Jane Street’s Avalo Therapeutics AVTX Stock Holding History

Jane Street’s Portfolio AVTX Stock Details AVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.59M	Sell	173,320 -5,535	-3%	-$86.5K	﹤0.01%	4614
2025 Q4	$3.25M	Buy	+178,855	New	+$3.02M	﹤0.01%	3921
2023 Q4	–	Sell	-115	Closed	-$3.32K	–	9163
2023 Q3	$3.32K	Buy	+115	New	+$5.14K	﹤0.01%	8466
2021 Q2	–	Sell	-4	Closed	-$31K	–	9755
2021 Q1	$31K	Buy	+4	New	+$37.8K	﹤0.01%	8924
2020 Q3	–	Sell	-5	Closed	-$37K	–	7127
2020 Q2	$37K	Buy	+5	New	+$36.3K	﹤0.01%	6905

Other funds holding AVTX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Jane Street's AVTX Position: Q1 2026 in Review

Jane Street reduced its Avalo Therapeutics (AVTX) stake by 3.1% in Q1 2026, selling an estimated $86.5K and leaving 173,320 shares worth $2.59M. The position accounts for ﹤0.01% of the portfolio, ranked #4614.

Jane Street first reported a position in AVTX in Q2 2020 and has held it in 5 quarters since. The position peaked at $3.25M in Q4 2025. 97 funds tracked by Wall St. Rank hold AVTX as of Q1 2026.

Jane Street held 173,320 shares of Avalo Therapeutics worth $2.59M as of Q1 2026.
Jane Street sold 5,535 Avalo Therapeutics shares in Q1 2026, an estimated $86.5K.
Avalo Therapeutics made up ﹤0.01% of Jane Street's portfolio in Q1 2026, its #4614 holding.
Jane Street first reported a position in Avalo Therapeutics in Q2 2020 and has held it in 5 quarters since.
Jane Street's Avalo Therapeutics position peaked at $3.25M in Q4 2025.
97 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q1 2026.

Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.